Pharmaceutical Technology21 小时
IC9 CAR.19 by Bellicum Pharmaceuticals for Primary CNS Lymphoma: Likelihood of Approval
IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Primary CNS Lymphoma.